IDIA — Idorsia Share News
0.000.00%
Last trade - 00:00- CH₣1.13bn
- CH₣2.28bn
- CH₣220.58m
Brief: Idorsia Q1 EBIT CHF 31 Million
Brief: Idorsia Says US GAAP Operating Loss Fy 2023 Of CHF 255 Million
Brief: Idorsia Says Proposed Consent Fee Will Be Increased To 8 Mln Idorsia Shares
Idorsia falls as it postpones results publication, reports short-term liquidity needs
Brief: Idorsia To Address Short-Term Liquidity Needs
Idorsia surges after FDA approves co's hypertension drug
Brief: FDA Approves Idorsia Pharma Ltd's Tryvio- Website
Viatris forecasts strong 2024 sales on higher demand for branded drugs
Brief: Idorsia And Viatris Enter Into Significant Global Research And Development Collaboration
Europe Research Roundup: Anglo American, Adevinta ASA, Auto Trader
Brief: Idorsia Reacquires The World-Wide Rights To Aprocitentan
Europe Research Roundup: Frontier Developments, Steico SE, Tyman
Brief: Idorsia H1 EBIT CHF -375 Million Vs. Estimate CHF -197 Million
Sosei buys Idorsia Pharmaceuticals' Japan, Korea units for $466 mln (updated)
Sosei buys Idorsia Pharmaceuticals' Japan, Korea units for $466 million - Nikkei
Brief: New Phase 3 Data With Aprocitentan For Patients With Resistant Hypertension Has Been Presented
Refinitiv Newscasts - UK Day Ahead: EZ sales flat but UK construction up; markets hit by rate jitters
Brief: Idorsia: Has Entered Into Exclusive Negotiations Regarding Operating Businesses In Asia Pacific (Ex-China) Region
Idorsia falls after Baader cuts to 'reduce'